Opinion

Video

When and How Often PSMA-PET Imaging Should be Used

Author(s):

Brian Helfand, MD, PhD,Gordon A. Brown, DO

Experts on prostate cancer discuss the ideal timing and frequency of PSMA-PET imaging and the role of different PSMA-PET agents.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      1 expert in this video
      Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
      1 expert in this video
      Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Study results affirm effectiveness of evolving prostate cancer therapies
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      1 expert in this video
      Comparing Trials Studying Treatment Intensification In mHSPC
      An Overview of the ARANOTE Trial
      An Overview of the ARANOTE Trial
      Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
      Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
      Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
      Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Related Content
      Study shows value of precision-based approaches in prostate cancer
      May 19th 2025

      Study shows value of precision-based approaches in prostate cancer

      Hannah Clarke
      The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
      May 6th 2025

      Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

      Hannah Clarke
      Initial study results may be available as soon as the first half of 2026.
      Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
      May 2nd 2025

      Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

      Hannah Clarke
      The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
      © 2025 MJH Life Sciences

      All rights reserved.